Vincent van der Noort

4.8k citations

133 papers · 2.5k indexed · 1 hit paper · h-index 23

Oncology top 2%
- Cancer Immunotherapy and Biomarkers 16
- Lung Cancer Research Studies 15
Pulmonary and Respiratory Medicine top 1%
- Lung Cancer Treatments and Mutations 30
- Lung Cancer Diagnosis and Treatment 12
- Prostate Cancer Treatment and Research 12
- Occupational and environmental lung diseases 10
Cancer Research top 5%
- Cancer Genomics and Diagnostics 13
- Breast Cancer Treatment Studies 11
Otorhinolaryngology top 5%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Paul Baas Kim Monkhorst Ferry Lalezari Jeltje F. de Vries Willemijn S.M.E. Theelen Joachim G.J.V. Aerts Idris Bahce Adrianus J. de Langen
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Oncology (10 papers)PLoS ONE (2 papers)Cancer (1 paper)
Partner nations: Netherlands United States Switzerland

In The Last Decade

Vincent van der Noort

120 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Vincent van der Noort

Since Specialization

Citations

This map shows the geographic impact of Vincent van der Noort's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent van der Noort with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent van der Noort more than expected).

Fields of papers citing papers by Vincent van der Noort

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent van der Noort. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent van der Noort. The network helps show where Vincent van der Noort may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vincent van der Noort, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vincent van der Noort Line = papers co-authored together Vincent van der Noort links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer JAMA Oncology ·Noor Wortelboer,Annemiek van Ommen-Nijhof,Inge R. Konings,Vincent van der Noort,E. van den Pol,Cristina Guerrero Páez,Sandra D. Bakker,Sjoerd Hovenga,A. Imholz,Yvonne J. L. Kamm,Lobke van Leeuwen,Sylvia A. Luykx-de Bakker,Caroline M. P. W. Mandigers,Johanna M. G. H. van Riel,Jolien Tol,Agnes J. van de Wouw,Saskia M. Wilting,A. Elise van Leeuwen-Stok,Agnes Jager,Gabe S. Sonke	2026	0
2	2096MO Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial Annals of Oncology ·Judith S. E. Quik,Karen van der Sluis,Vincent van der Noort,Valesca P. Retèl,M. Luyer,Irene E.G. van Hellemond,Bas P. L. Wijnhoven,Bianca Mostert,Richard van Hillegersberg,Nadia Haj Mohammad,Boudewijn van Etten,Derk Jan de Groot,Olli Helminen,Jakob Hedberg,Paul Cashin,Daniel Willy Kjær,Liudmila L. Kodach,Marieke A. Vollebergh,Johanna van Sandick	2025	0
3	The feasibility of using real world data as external control arms in oncology trials Drug Discovery Today ·Lishi Lin,Merel J J Lucassen,Vincent van der Noort,Toine C. G. Egberts,J. H. Beijnen,Alwin D. R. Huitema	2025	1
4	Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial European Journal of Cancer ·Noor Wortelboer,Seamus Kent,Inge R. Konings,Annemiek van Ommen‐Nijhof,Vincent van der Noort,E. van den Pol,Cristina Guerrero Páez,Marlies L. van Bekkum,F. Van den Berkmortel,Helga Droogendijk,Danny Houtsma,Hendrika M. Oosterkamp,Annemieke van der Padt‐Pruijsten,Ester Siemerink,Jolien Tol,Annette A. van Zweeden,A. Elise van Leeuwen‐Stok,Gabe S. Sonke,Agnes Jager,Hedwig M. Blommestein	2025	1
5	1258MO Low dose versus standard dose pembrolizumab for treatment of stage IV stage non-small cell lung carcinoma: Results of the pre-planned interim analysis of the NVALT-30 clinical trial Annals of Oncology ·M. van den Heuvel,Vincent van der Noort,Rob ter Heine	2024	6
6	Omission of axillary lymph node dissection in cN2-3 breast cancer patients with an excellent response on primary systemic treatment is safe: 4-year oncologic outcome of the MARI protocol European Journal of Cancer ·Albert van Hemert,Ariane A. van Loevezijn,Martijn Baas,Marcel P. M. Stokkel,Ewout J. N. Groen,Claudette E. Loo,Vincent van der Noort,Gabe S. Sonke,N.S. Russell,Frederieke van Duijnhoven,Marcus Peeters	2024	1
7	352P Cost-effectiveness of CDK4/6 inhibitors in first- vs second-line for advanced breast cancer (ABC) in the phase III SONIA trial (BOOG 2017-03) Annals of Oncology ·Noor Wortelboer,Stephen B. H. Kent,Inge R. Konings,Annemiek van Ommen‐Nijhof,Vincent van der Noort,E. van den Pol,Cristina Guerrero Páez,M. van Bekkum,H.J. Droogendijk,Frans Erdkamp,Danny Houtsma,Hendrika M. Oosterkamp,Annemieke van der Padt‐Pruijsten,E.J. Siemerink,J. Tol,Annette A. van Zweeden,A. Elise van Leeuwen‐Stok,Gabe S. Sonke,Agnes Jager,Hedwig M. Blommestein	2024	1
8	Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol Clinical Cancer Research ·Karlijn Verkerk,Tijmen J.W.T. van der Wel,Laurien J. Zeverijn,Birgit S. Geurts,Ilse A.C. Spiekman,Gijs F. de Wit,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort,Egbert F. Smit,Ann Hoeben,Lizza Hendriks,Michel M. van den Heuvel,Berber Piet,Gerarda J.M. Herder,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,Adrianus J. de Langen	2024	1
9	Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol Clinical Cancer Research ·Jade M. van Berge Henegouwen,Laurien J. Zeverijn,Birgit S. Geurts,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Alwin D. R. Huitema,Filip De Vos,Katrien Grünberg,Haiko J. Bloemendal,Henk M.W. Verheul,Emile E. Voest,Hans Gelderblom	2024	1
10	Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer PLoS ONE ·Karlijn Hummelink,Vincent van der Noort,Mirte Muller,Robert D. Schouten,Michel M. van den Heuvel,Daniela S. Thommen,Egbert F. Smit,Gerrit A. Meijer,Kim Monkhorst	2024	2
11	Optimising primary molecular profiling in non-small cell lung cancer PLoS ONE ·Robert D. Schouten,Ineke Schouten,Milou Schuurbiers,Vincent van der Noort,Ronald Damhuis,Erik H.F.M. van der Heijden,J. A. Burgers,Nicole P. Barlo,Anne S. R. van Lindert,K.W. Maas,J. J. G. van den Brand,Annet Smit,J.M.W. van Haarst,B. Maat,Ed Schuuring,Hans Blaauwgeers,Stefan M. Willems,Kim Monkhorst,Daan van den Broek,Michel M. van den Heuvel	2024	1
12	Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy Clinical Genitourinary Cancer ·Kim van der Zande,Rebecca D Tutuhatunewa-Louhanepessy,Paul Hamberg,Sb Ras,J.M. de Feijter,V.O. Dezentjé,Annegien Broeks,Sten Cornelissen,Aart Beeker,Vincent van der Noort,Wilbert Zwart,Andries M. Bergman	2024	2
13	Histopathological Concordance between Prostate Biopsies and Radical Prostatectomy Specimens – Implications of Transrectal and Transperineal Biopsy Approaches European Urology Open Science ·M.J. Hagens,L.L.A. Ribbert,A. Jager,Hans Veerman,Kurdo Barwari,B. Boodt,Roderick E. de Bruijn,A.M.E. Claessen,M.R. Leter,Vincent van der Noort,Martijn Smeenge,Ton A. Roeleveld,S.P. Rynja,M. Schaaf,Saskia Weltings,André N. Vis,Elise M. Bekers,Pim J. van Leeuwen,Henk G. van der Poel	2023	1
14	1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP) Annals of Oncology ·Karin Verkerk,Twan van der Wel,Laurien J. Zeverijn,Birgit S. Geurts,Ilse A.C. Spiekman,G.F. de Wit,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort,Egbert F. Smit,Ann Hoeben,Lizza Hendriks,Carla M.L. van Herpen,Berber Piet,G. Herder,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,J. De Langen	2023	3
15	Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC JTO Clinical and Research Reports ·M. Jebbink,Adrianus J. de Langen,Kim Monkhorst,Mirjam C. Boelens,Daan van den Broek,Vincent van der Noort,Cornedine J. de Gooijer,M. Mahn,Anthonie J. van der Wekken,Lizza Hendriks,Sayed M.S. Hashemi,Marthe S. Paats,Anne‐Marie C. Dingemans,Egbert F. Smit	2023	19
16	PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC Clinical Cancer Research ·Karlijn Hummelink,Vincent van der Noort,Mirte Muller,Robert D. Schouten,Ferry Lalezari,Dennis Peters,Willemijn S.M.E. Theelen,Viktor H. Koelzer,Kirsten D. Mertz,Alfred Zippelius,Michel M. van den Heuvel,Annegien Broeks,John B.A.G. Haanen,Ton N. Schumacher,Gerrit A. Meijer,Egbert F. Smit,Kim Monkhorst,Daniela S. Thommen	2022	26
17	The oncological characteristics of non‐prostate‐specific membrane antigen (PSMA)‐expressing primary prostate cancer on preoperative PSMA positron emission tomography/computed tomography British Journal of Urology ·Hans Veerman,Maarten L. Donswijk,Elise M. Bekers,Yves J. L. Bodar,Dennie Meijer,R. Jeroen A. van Moorselaar,Daniela E. Oprea‐Lager,Vincent van der Noort,Pim J. van Leeuwen,André N. Vis,Henk G. van der Poel	2022	6
18	Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer European Journal of Cancer ·Jade M. van Berge Henegouwen,M. Jebbink,Louisa R. Hoes,Hanneke van der Wijngaart,Laurien J. Zeverijn,Daphne van der Velden,Paul Roepman,Wendy W.J. de Leng,Anne M.L. Jansen,Erik van Werkhoven,Vincent van der Noort,Anthonie J. van der Wekken,Adrianus J. de Langen,Emile E. Voest,Henk M.W. Verheul,Egbert F. Smit,Hans Gelderblom	2022	16
19	Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer? Lung Cancer ·Pieter J.M. Joosten,Chris Dickhoff,Vincent van der Noort,Houke M. Klomp,Judi N.A. van Diessen,Max Dahele,Idris Bahce,Alexander A. F. A. Veenhof,Egbert F. Smit,Koen J. Hartemink	2020	3
20	PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane Journal of Cancer Research and Clinical Oncology ·Dinja T. Kruger,Mark Opdam,Vincent van der Noort,Joyce Sanders,Michiel Nieuwenhuis,Bart de Valk,Karin Beelen,Sabine C. Linn,Epie Boven	2020	6

About Vincent van der Noort

Vincent van der Noort is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 133 papers that have together received 2.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Research Studies (15 papers), Cancer Genomics and Diagnostics (13 papers), Lung Cancer Diagnosis and Treatment (12 papers), Prostate Cancer Treatment and Research (12 papers), Breast Cancer Treatment Studies (11 papers) and Occupational and environmental lung diseases (10 papers). The work is most often cited by research in Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.4k citations) and Cancer Research (362 citations). Vincent van der Noort has collaborated with scholars based in Netherlands, United States and Switzerland. Frequent co-authors include Paul Baas, Kim Monkhorst, Ferry Lalezari, Jeltje F. de Vries, Willemijn S.M.E. Theelen, Joachim G.J.V. Aerts, Idris Bahce, Adrianus J. de Langen, Daphne W. Dumoulin and Heike Peulen. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact